<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DAUNORUBICIN HYDROCHLORIDE- daunorubicin hydrochloride injection, solution </strong><br>Teva Parenteral Medicines, Inc.<br></p></div>
<h1>DAUNORUBICIN <br>Hydrochloride Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9525de24-613f-47ff-acaa-0cb04e91b547"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Package Insert</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Warning">
<a name="id_352adb1b-133d-40c7-94d7-1a5872d7f89f"></a><a name="section-2"></a><p></p>
<h1>WARNINGS</h1>
<ol>
<li>Daunorubicin hydrochloride injection must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> will occur if there is <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> during administration.</li>
<li>Myocardial toxicity manifested in its most severe form by potentially fatal <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m<span class="Sup">2</span> in adults, 300 mg/m<span class="Sup">2</span> in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age.</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> occurs when used in therapeutic doses; this may lead to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</li>
<li>It is recommended that daunorubicin hydrochloride be administered only by physicians who are experienced in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">drug toxicity</span>. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>Dosage should be reduced in patients with impaired hepatic or renal function.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_5d75d44b-a6eb-40d4-a19d-717d174d0d08"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Daunorubicin Hydrochloride Injection consists of the hydrochloride salt of an anthracycline cytotoxic antibiotic produced by a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Streptomyces coeruleorubidus</span>. It is provided as a deep red sterile liquid in vials for intravenous administration only. Each mL contains daunorubicin hydrochloride, USP equivalent to 5 mg of daunorubicin, 9 mg sodium chloride, hydrochloric acid (to adjust pH), and water for injection, q.s. It has the following structural formula which may be described with the chemical name of (1<span class="Italics">S</span>,3<span class="Italics">S</span>)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-α-L-<span class="Italics">lyxo</span>-hexopyranoside hydrochloride.</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b8a5ad9-9e34-4f88-997c-244d9a0ef2c2&amp;name=b4f2e95a-37fb-41f9-b8be-c96c884a5498-01.jpg"></div>
<p>                               C<span class="Sub">27</span>H<span class="Sub">29</span>NO<span class="Sub">10</span>•HCl                M.W. 563.99</p>
<p>It is a hygroscopic crystalline powder. The pH of a 5 mg/mL aqueous solution is 3 to 4.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_69f62002-cb61-4364-84b8-1123c15d2549"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_d159ca51-6105-4b95-928a-8feb58321eba"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Single strand and double strand DNA breaks result.</p>
<p>Daunorubicin hydrochloride may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA.</p>
<p>Daunorubicin hydrochloride possesses an antitumor effect against a wide spectrum of animal tumors, either grafted or spontaneous.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_84b76e3b-3b13-470a-8d6e-ca2dce9d4780"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54c1b45c-3fc4-4ddd-bd70-2beebd3bc3a1"></a><a name="section-3.2.1"></a><p></p>
<h3>General</h3>
<p class="First">Following intravenous injection of daunorubicin hydrochloride, plasma levels of daunorubicin decline rapidly, indicating rapid tissue uptake and concentration. Thereafter, plasma levels decline slowly with a half-life of 45 minutes in the initial phase and 18.5 hours in the terminal phase. By 1 hour after drug administration, the predominant plasma species is daunorubicinol, an active metabolite, which disappears with a half-life of 26.7 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c2cc757-7673-4983-be14-e38153ac581a"></a><a name="section-3.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Daunorubicin hydrochloride is rapidly and widely distributed in tissues, with highest levels in the spleen, kidneys, liver, lungs, and heart. The drug binds to many cellular components, particularly nucleic acids. There is no evidence that daunorubicin crosses the blood-brain barrier, but the drug apparently crosses the placenta.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_33bffb6a-e4f6-4a6b-a322-9ace018726bd"></a><a name="section-3.2.3"></a><p></p>
<h3>Metabolism and Elimination</h3>
<p class="First">Daunorubicin hydrochloride is extensively metabolized in the liver and other tissues, mainly by cytoplasmic aldo-keto reductases, producing daunorubicinol, the major metabolite which has antineoplastic activity. Approximately 40% of the drug in the plasma is present as daunorubicinol within 30 minutes and 60% in 4 hours after a dose of daunorubicin. Further metabolism via reduction cleavage of the glycosidic bond, 4-O demethylation, and conjugation with both sulfate and glucuronide have been demonstrated. Simple glycosidic cleavage of daunorubicin or daunorubicinol is not a significant metabolic pathway in man. Twenty-five percent of an administered dose of daunorubicin hydrochloride is eliminated in an active form by urinary excretion and an estimated 40% by biliary excretion.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d26cf9d7-4a0a-4180-930e-02daa206a3fe"></a><a name="section-3.3"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a227741-8f96-4b87-80fb-df134a42e513"></a><a name="section-3.3.1"></a><p></p>
<h3>Pediatric Patients</h3>
<p class="First">Although appropriate studies with daunorubicin hydrochloride have not been performed in the pediatric population, cardiotoxicity may be more frequent and occur at lower cumulative doses in children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a733a39b-5e9f-4d04-9269-3bf5be8ea0c1"></a><a name="section-3.3.2"></a><p></p>
<h3>Geriatric Patients</h3>
<p class="First">Although appropriate studies with daunorubicin hydrochloride have not been performed in the geriatric population, cardiotoxicity may be more frequent in the elderly. Caution should also be used in patients who have inadequate bone marrow reserves due to old age. In addition, elderly patients are more likely to have age-related renal function impairment, which may require reduction of dosage in patients receiving daunorubicin hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_448155bb-4e05-4384-91c3-eeb718f17f4e"></a><a name="section-3.3.3"></a><p></p>
<h3>Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h3>
<p class="First">Doses of daunorubicin hydrochloride should be reduced in patients with hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with serum bilirubin concentrations of 1.2 to 3 mg/dL should receive 75% of the usual daily dose and patients with serum bilirubin concentrations greater than 3 mg/dL should receive 50% of the usual daily dose. Patients with serum creatinine concentrations of greater than 3 mg/dL should receive 50% of the usual daily dose (see <span class="Bold"><a href="#i4i_section_id_4004faae-01dc-486b-8308-3a45912adf4f">WARNINGS, Evaluation of Hepatic and Renal Function</a></span>section).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_fdfb63a3-6a2e-4e7a-b68d-93e52e1b43e6"></a><a name="section-3.4"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">In the treatment of adult acute nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, daunorubicin hydrochloride, used as a single agent, has produced complete remission rates of 40 to 50%, and in combination with cytarabine, has produced complete remission rates of 53 to 65%.</p>
<p>The addition of daunorubicin hydrochloride to the two-drug induction regimen of vincristine-prednisone in the treatment of childhood <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span> does not increase the rate of complete remission. In children receiving identical CNS prophylaxis and maintenance therapy (without consolidation), there is prolongation of complete remission duration (statistically significant, p &lt; 0.02) in those children induced with the three drug (daunorubicin-vincristine-prednisone) regimen as compared to two drugs. There is no evidence of any impact of daunorubicin hydrochloride on the duration of complete remission when a consolidation (intensification) phase is employed as part of a total treatment program.</p>
<p>In adult <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span>, in contrast to childhood <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span>, daunorubicin hydrochloride during induction significantly increases the rate of complete remission, but not remission duration, compared to that obtained with vincristine, prednisone, and L-asparaginase alone. The use of daunorubicin hydrochloride in combination with vincristine, prednisone, and L-asparaginase has produced complete remission rates of 83% in contrast to a 47% remission in patients not receiving daunorubicin hydrochloride.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_320d949a-e02a-42ec-afca-606affb37213"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (myelogenous, monocytic, erythroid) of adults and for remission induction in <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span> of children and adults.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_c7bcc869-e2f7-4e01-8003-12d15b2c511a"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Daunorubicin hydrochloride is contraindicated in patients who have shown a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_e80f23d7-b623-4dfb-8bbf-7dfa997af801"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e043cc88-9ffc-4172-9a1c-7e8b3bc388b5"></a><a name="section-6.1"></a><p></p>
<h2>Bone Marrow</h2>
<p class="First">Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of this drug. Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may result in <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9e8a9d2-96f6-4381-b501-0eec12671682"></a><a name="section-6.2"></a><p></p>
<h2>Cardiac Effects</h2>
<p class="First">Special attention must be given to the potential cardiac toxicity of daunorubicin hydrochloride, particularly in infants and children. Preexisting heart disease and previous therapy with doxorubicin are co-factors of increased risk of daunorubicin-induced cardiac toxicity and the benefit-to-risk ratio of daunorubicin hydrochloride therapy in such patients should be weighed before starting daunorubicin hydrochloride. In adults, at total cumulative doses less than 550 mg/m<span class="Sup">2</span>, acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> is seldom encountered. However, rare instances of <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>-<span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, not dose-related, have been reported.</p>
<p>In adults, at cumulative doses exceeding 550 mg/m<span class="Sup">2</span>, there is an increased incidence of drug-induced <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Based on prior clinical experience with doxorubicin, this limit appears lower, namely 400 mg/m<span class="Sup">2</span>, in patients who received radiation therapy that encompassed the heart.</p>
<p>In infants and children, there appears to be a greater susceptibility to anthracycline-induced cardiotoxicity compared to that in adults, which is more clearly dose-related. Anthracycline therapy (including daunorubicin) in pediatric patients has been reported to produce impaired left ventricular systolic performance, reduced contractility, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. These conditions may occur months to years following cessation of chemotherapy. This appears to be dose-dependent and aggravated by thoracic irradiation. Long-term periodic evaluation of cardiac function in such patients should, thus, be performed. In both children and adults, the total dose of daunorubicin hydrochloride administered should also take into account any previous or concomitant therapy with other potentially cardiotoxic agents or related compounds such as doxorubicin.</p>
<p>There is no absolutely reliable method of predicting the patients in whom acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> will develop as a result of the cardiac toxic effect of daunorubicin hydrochloride. However, certain changes in the electrocardiogram and a decrease in the systolic <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> from pretreatment baseline may help to recognize those patients at greatest risk to develop <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. On the basis of the electrocardiogram, a decrease equal to or greater than 30% in limb lead QRS voltage has been associated with a significant risk of drug-induced <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. Therefore, an electrocardiogram and/or determination of systolic <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> should be performed before each course of daunorubicin hydrochloride. In the event that one or the other of these predictive parameters should occur, the benefit of continued therapy must be weighed against the risk of producing cardiac damage.</p>
<p>Early clinical diagnosis of drug-induced <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> appears to be essential for successful treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4004faae-01dc-486b-8308-3a45912adf4f"></a><a name="section-6.3"></a><p></p>
<h2>Evaluation of Hepatic and Renal Function</h2>
<p class="First">Significant hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> can enhance the toxicity of the recommended doses of daunorubicin hydrochloride; therefore, prior to administration, evaluation of hepatic function and renal function using conventional clinical laboratory tests is recommended (see <span class="Bold"><a href="#i4i_dosage_admin_id_04dafddf-6a26-4ea7-9029-c5155fd6f28b">DOSAGE AND ADMINISTRATION</a></span>section).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b0f710b0-7d42-4c4f-aa20-d48ac416ac01"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Daunorubicin hydrochloride may cause fetal harm when administered to a pregnant woman. An increased incidence of fetal abnormalities (parieto-occipital cranioschisis, <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernias</span>, or rachischisis) and abortions was reported in rabbits at doses of 0.05 mg/kg/day or approximately 1/100th of the highest recommended human dose on a body surface area basis. Rats showed an increased incidence of esophageal, cardiovascular and urogenital abnormalities as well as rib fusions at doses of 4 mg/kg/day or approximately 1/2 the human dose on a body surface area basis. Decreases in fetal birth weight and post-delivery growth rate were observed in mice. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f00c59d-fd6b-48d4-8618-8a908dbc7f17"></a><a name="section-6.5"></a><p></p>
<h2>Secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemias</span></h2>
<p class="First">There have been reports of secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> in patients exposed to topoisomerase II inhibitors when used in combination with other antineoplastic agents or radiation therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f61fa89f-1956-4280-bd0b-b7a28444087e"></a><a name="section-6.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> at Injection Site</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of daunorubicin hydrochloride at the site of intravenous administration can cause severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> (see <span class="Bold"><a href="#i4i_adverse_effects_id_a6548e91-452c-4663-8a10-9e0da5a70a0c">ADVERSE REACTIONS</a></span>section).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_ee5a5dc6-d1d6-4c8d-ba59-90c9d426da53"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_caf0c47c-3e9b-4b09-bbfa-610e00d1cf81"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Therapy with daunorubicin hydrochloride requires close patient observation and frequent complete blood-count determinations. Cardiac, renal, and hepatic function should be evaluated prior to each course of treatment.</p>
<p>Appropriate measures must be taken to control any systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> before beginning therapy with daunorubicin hydrochloride.</p>
<p>Daunorubicin hydrochloride may transiently impart a red coloration to the urine after administration, and patients should be advised to expect this.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_e708a99c-7ce9-4062-a2b6-97910a75e82c"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Daunorubicin hydrochloride may induce <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> secondary to rapid lysis of leukemic cells. As a precaution, allopurinol administration is usually begun prior to initiating antileukemic therapy. Blood uric acid levels should be monitored and appropriate therapy initiated in the event that <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> develops.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_32273990-49b5-487c-b965-e4e5c8ffd170"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Daunorubicin hydrochloride, when injected subcutaneously into mice, causes a <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcomas</span> to develop at the injection site. When administered to mice thrice weekly intraperitoneally, no carcinogenic effect was noted after 18 months of observation. In male rats administered daunorubicin thrice weekly for 6 months, at 1/70th the recommended human dose on a body surface area basis, peritoneal <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> were found at 18 months. A single IV dose of daunorubicin administered to rats at 1.6 fold the recommended human dose on a body surface area basis caused mammary adenocarcinomas to appear at 1 year. Daunorubicin was mutagenic in vitro (Ames assay, V79 hamster cell assay), and clastogenic in vitro (CCRFCEM human lymphoblasts) and in vivo (SCE assay in mouse bone marrow) tests.</p>
<p>In male dogs at a daily dose of 0.25 mg/kg administered intravenously, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> was noted at autopsy. Histologic examination revealed total <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> of the spermatocyte series in the seminiferous tubules with complete aspermatogenesis.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_62bca8df-95c6-4cdc-91b2-dfdfde33fb48"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy Category D</h2>
<p class="First">See <span class="Bold"><a href="#i4i_warnings_id_e80f23d7-b623-4dfb-8bbf-7dfa997af801">WARNINGS</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d392b118-43b2-4233-8398-20968175ebc1"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from daunorubicin, mothers should be advised to discontinue nursing during daunorubicin therapy.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_a3a67479-57e5-478d-9197-89be143db97e"></a><a name="section-7.6"></a><p></p>
<h2>Elderly</h2>
<p class="First">See <span class="Bold"><a href="#i4i_section_id_a733a39b-5e9f-4d04-9269-3bf5be8ea0c1">CLINICAL PHARMACOLOGY, Special Populations, Geriatric Patients</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_b402c927-f03a-49b8-ade5-02979e96ae9c"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold"><a href="#i4i_section_id_7a227741-8f96-4b87-80fb-df134a42e513">CLINICAL PHARMACOLOGY, Special Populations, Pediatric Patients</a></span> section and <span class="Bold"><a href="#i4i_section_id_e9e8a9d2-96f6-4381-b501-0eec12671682">WARNINGS, Cardiac Effects</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_a20e5dfd-e476-492c-9f2f-49c218154e68"></a><a name="section-7.8"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Use of daunorubicin in a patient who has previously received doxorubicin increases the risk of cardiotoxicity. Daunorubicin hydrochloride should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or daunorubicin hydrochloride. Cyclophosphamide used concurrently with daunorubicin hydrochloride may also result in increased cardiotoxicity.</p>
<p>Dosage reduction of daunorubicin hydrochloride may be required when used concurrently with other myelosuppressive agents.</p>
<p>Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a6548e91-452c-4663-8a10-9e0da5a70a0c"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Dose-limiting toxicity includes <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and cardiotoxicity (see <span class="Bold"><a href="#i4i_warnings_id_e80f23d7-b623-4dfb-8bbf-7dfa997af801">WARNINGS</a></span>section). Other reactions include:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da880f33-b6b6-45fb-80d3-05b421f2126c"></a><a name="section-8.1"></a><p></p>
<h2>Cutaneous</h2>
<p class="First">Reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> occurs in most patients. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have occurred rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_19fad75b-8261-4132-95bb-80f741493b11"></a><a name="section-8.2"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Acute <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occur but are usually mild. Antiemetic therapy may be of some help. <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucositis</span> may occur 3 to 7 days after administration. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> have occasionally been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c60aa97-fe68-485c-b0d4-5f3a7fcc00cd"></a><a name="section-8.3"></a><p></p>
<h2>Local</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occurs during administration, severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, severe <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, or painful <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> can result.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e9a7764-85e8-4648-841a-46987979396e"></a><a name="section-8.4"></a><p></p>
<h2>Acute Reactions</h2>
<p class="First">Rarely, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> can occur. <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur, especially in patients with <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, and serum uric acid levels should be monitored.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_04dafddf-6a26-4ea7-9029-c5155fd6f28b"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c47facc-223d-4522-b092-e4561944cbb4"></a><a name="section-9.1"></a><p></p>
<h2>Principles</h2>
<p class="First">In order to eradicate the leukemic cells and induce a complete remission, a profound suppression of the bone marrow is usually required. Evaluation of both the peripheral blood and bone marrow is mandatory in the formulation of appropriate treatment plans.</p>
<p>It is recommended that the dosage of daunorubicin hydrochloride be reduced in instances of hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. For example, using serum bilirubin and serum creatinine as indicators of liver and kidney function, the following dose modifications are recommended:</p>
<a name="id_750cacdb-71ea-4b09-a553-877e6df23e56"></a><table width="430.000">
<col align="center" width="34.0%">
<col align="center" width="33.0%">
<col align="center" width="33.0%">
<thead><tr class="Botrule First Last">
<td class="Botrule Rrule" align="left" valign="top">Serum Bilirubin</td>
<td class="Botrule Rrule" align="left" valign="top">Serum Creatinine</td>
<td class="Botrule" align="left" valign="top">Dose Reduction</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">1.2 to 3 mg%</td>
<td class="Toprule" align="left" valign="top">—</td>
<td align="left" valign="top">25%</td>
</tr>
<tr>
<td align="left" valign="top">&gt; 3 mg%</td>
<td align="left" valign="top">—</td>
<td align="left" valign="top">50%</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">—</td>
<td align="left" valign="top">&gt; 3 mg%</td>
<td align="left" valign="top">50%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7467e8b6-1416-40ac-987d-8899626df50f"></a><a name="section-9.2"></a><p></p>
<h2>Representative Dose Schedules and Combination for the Approved Indication of Remission Induction in Adult Acute Nonlymphocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc729bad-dc19-4bfa-b8b9-f44dd79d0549"></a><a name="section-9.2.1"></a><p></p>
<h3>In Combination</h3>
<p class="First">For patients under age 60, daunorubicin hydrochloride 45 mg/m<span class="Sup">2</span>/day IV on days 1, 2, and 3 of the first course and on days 1, 2 of subsequent courses AND cytosine arabinoside 100 mg/m<span class="Sup">2</span>/day IV infusion daily for 7 days for the first course and for 5 days for subsequent courses.</p>
<p>For patients 60 years of age and above, daunorubicin hydrochloride 30 mg/m<span class="Sup">2</span>/day IV on days 1, 2, and 3 of the first course and on days 1, 2 of subsequent courses AND cytosine arabinoside 100 mg/m<span class="Sup">2</span>/day IV infusion daily for 7 days for the first course and for 5 days for subsequent courses. This daunorubicin hydrochloride dose-reduction is based on a single study and may not be appropriate if optimal supportive care is available.</p>
<p>The attainment of a normal-appearing bone marrow may require up to three courses of induction therapy. Evaluation of the bone marrow following recovery from the previous course of induction therapy determines whether a further course of induction treatment is required.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e4aa1d0-fe12-480a-8513-b2133a5b4d81"></a><a name="section-9.3"></a><p></p>
<h2>Representative Dose Schedule and Combination for the Approved Indication of Remission Induction in Pediatric <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphocytic Leukemia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0272e05c-5a5d-4068-b8b4-b5bce4bd9bea"></a><a name="section-9.3.1"></a><p></p>
<h3>In Combination</h3>
<p class="First">Daunorubicin hydrochloride 25 mg/m<span class="Sup">2</span> IV on day 1 every week, vincristine 1.5 mg/m<span class="Sup">2</span> IV on day 1 every week, prednisone 40 mg/m<span class="Sup">2</span> PO daily. Generally, a complete remission will be obtained within four such courses of therapy; however, if after four courses the patient is in partial remission, an additional one or, if necessary, two courses may be given in an effort to obtain a complete remission.</p>
<p>In children less than 2 years of age or below 0.5 m<span class="Sup">2</span> body surface area, it has been recommended that the daunorubicin hydrochloride dosage calculation should be based on weight (1 mg/kg) instead of body surface area.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01a0b5da-0a18-48e1-b209-b6100fc7efb3"></a><a name="section-9.4"></a><p></p>
<h2>Representative Dose Schedules and Combination for the Approved Indication of Remission Induction in Adult <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphocytic Leukemia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e147d01d-fa11-42f6-b3f5-c99376836403"></a><a name="section-9.4.1"></a><p></p>
<h3>In Combination</h3>
<p class="First">Daunorubicin hydrochloride 45 mg/m<span class="Sup">2</span>/day IV on days 1, 2, and 3 AND vincristine 2 mg IV on days 1, 8, and 15; prednisone 40 mg/m<span class="Sup">2</span>/day PO on days 1 through 22, then tapered between days 22 to 29; L-asparaginase 500 IU/kg/day X 10 days IV on days 22 through 32.</p>
<p>The sterile 4 mL vial contents provide 20 mg of daunorubicin with 5 mg of daunorubicin per mL. The desired dose is withdrawn into a syringe containing 10 mL to 15 mL of 0.9% sodium chloride injection, USP and then injected into the tubing or sidearm in a rapidly flowing IV infusion of 5% dextrose injection, USP or 0.9% sodium chloride injection, USP. <span class="Bold">Daunorubicin hydrochloride should not be administered mixed with other drugs or heparin.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_71e5557a-fe0c-432e-a6f0-7245709893ff"></a><a name="section-10"></a><p></p>
<h1>Storage and Handling</h1>
<p class="First">Store unopened vials in refrigerator, 2° to 8°C (36° to 46°F). Store prepared solution for infusion at room temperature, 20° to 25°C (68° to 77°F) for up to 24 hours. Contains no preservative. Discard unused portion. <span class="Bold">Protect from light. Retain in carton until time of use.</span></p>
<p>If daunorubicin hydrochloride contacts the skin or mucosae, the area should be washed thoroughly with soap and water. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.<span class="Sup">1-7</span> There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_026f5fe8-3bbb-40d1-adab-4b80a0f86a4c"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Daunorubicin Hydrochloride Injection, 5 mg (base)/mL, is available as follows:</p>
<a name="id_b9f66653-59f6-45ef-96d3-1631dc1b59bc"></a><table width="430.000">
<col align="left" width="33.0%">
<col align="left" width="33.0%">
<col align="left" width="34.0%">
<thead><tr class="Botrule First Last">
<td class="Botrule Rrule" align="left" valign="top">NDC Number</td>
<td class="Botrule Rrule" align="left" valign="top">Contents</td>
<td class="Botrule" align="left" valign="top">Size</td>
</tr></thead>
<tbody><tr class="Botrule First Last">
<td align="left" valign="top">0703-5233-93</td>
<td align="left" valign="top">20 mg<br>(as base)</td>
<td align="left" valign="top">4 mL fill in a 6 mL Single Dose Vial</td>
</tr></tbody>
</table>
<p>The 20 mg base/4 mL vials are packaged in tens.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_fbffb4ed-f38a-4491-b99e-5b4b16f69d31"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For Sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402.</li>
<li>AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. JAMA. 253 (11): 1590–1592, 1985.</li>
<li>National Study Commission on Cytotoxic Exposure—Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.</li>
<li>Clinical Oncological Society of Australia: Guidelines and recommendations for safe handling of antineoplastic agents. Med J Australia 1:426–428, 1983.</li>
<li>Jones RB, et al.: Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center, Ca – A Cancer Journal for Clinicians Sept/Oct, 258–263, 1983.</li>
<li>American Society of Hospital Pharmacists technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 47:1033–1049, 1990.</li>
<li>OSHA Work Practice Guidelines for Personnel Dealing with Cyotoxic (Antineoplastic) Drugs. AM J Hosp Pharm 43:1193–1204, 1986.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f37f405-ca1e-4a68-8147-edb89fb201ca"></a><a name="section-13"></a><p></p>
<p class="First">Iss. 9/2012</p>
<p>Manufactured By:</p>
<p>Teva Parenteral Medicines, Inc.<br>Irvine, CA 92618 </p>
<p>Novation and NOVAPLUS</p>
<p>are registered trademarks of Novation, LLC.</p>
<p>NOVAPLUS<span class="Sup">®</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_c53af532-342a-425b-8538-37cd3d8f4c2a"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL </h1>
<div class="Figure"><img alt="Daunorubicin Hydrochloride Injection 20 mg/4mL 10 Vials Tray Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4b8a5ad9-9e34-4f88-997c-244d9a0ef2c2&amp;name=b4f2e95a-37fb-41f9-b8be-c96c884a5498-02.jpg"></div>
<p class="First"><span class="Bold">DAUNORUBICIN Hydrochloride Injection 20 mg/4 mL, 10 Single Dose Vial Tray Label Text</span></p>
<p>NDC 0703-5233-93  <span class="Bold">        Rx only</span></p>
<p><span class="Bold">DAUNORUBICIN</span></p>
<p><span class="Bold">Hydrochloride Injection</span></p>
<p>For IV Use Only               <span class="Bold">10 Vials</span></p>
<p><span class="Bold">Cytotoxic Agent</span></p>
<p><span class="Bold">4 mL Single Dose Vial</span></p>
<p><span class="Bold">20 mg/</span></p>
<p><span class="Bold">4 mL</span></p>
<p><span class="Bold">(5 mg/mL*)</span></p>
<p>Manufactured By:</p>
<p>Teva Parenteral Medicines, Inc.</p>
<p>Irvine, CA 92618</p>
<p>Novation and NOVAPLUS are registered</p>
<p>trademarks of Novation, LLC.</p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span>                               Iss. 9/2012</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DAUNORUBICIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">daunorubicin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0703-5233</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DAUNORUBICIN HYDROCHLORIDE</strong> (DAUNORUBICIN) </td>
<td class="formItem">DAUNORUBICIN</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-5233-93</td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-5233-91</td>
<td class="formItem">4 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065035</td>
<td class="formItem">04/01/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Parenteral Medicines, Inc.
							(794362533)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b4f2e95a-37fb-41f9-b8be-c96c884a5498</div>
<div>Set id: 4b8a5ad9-9e34-4f88-997c-244d9a0ef2c2</div>
<div>Version: 1</div>
<div>Effective Time: 20121220</div>
</div>
</div> <div class="DistributorName">Teva Parenteral Medicines, Inc.</div></p>
</body></html>
